Format

Send to

Choose Destination
Anticancer Res. 2002 Jul-Aug;22(4):2147-51.

Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain.

Author information

1
Unité mixte Université Joseph Fourier/INSERM U438, LCR CEA, Grenoble, France. Michel.Peoch@chu-grenoble.fr

Abstract

BACKGROUND:

Recent papers suggest that two angiogenic factors (angiopoietin 2 and vascular endothelial growth factor) cooperate in tumoral angiogenesis to support the growing tumor. The purpose of the present work was to demonstrate the existence of such cooperation in a longitudinal study of a brain tumor model during tumor growth by means of immunohistochemistry.

MATERIALS AND METHODS:

The study was performed on 31 rats bearing C6 glioma. At different stages of tumor growth, the histological aspects were described and sections were immunostained for VEGF, Ang-2 and their receptors VEGFR-1, VEGFR-2 and Tie-2. Immunostaining was semi-quantitatively analyzed and the localization of immunostained cells was reported.

RESULTS:

Ang-2 and Tie-2 were detected in the endothelial cells of vessels surrounded by tumor cells, occuring early in our study, with immunostaining taking place from day 4 to day 24. Immunostaining with VEGF (on tumoral cells) and VEGFR-2 (on endothelial cells) was present after 8 days of tumor growth. A clear increase of vessel density can be observed at the periphery of the tumors after 16 days of tumor growth. At that time, areas of necrosis were present in the tumor with concomitant VEGF and Ang-2 expression.

CONCLUSION:

The present study demonstrated cooperation between the early effect of Ang-2 and the secondary effect of VEGF to elaborate new vessels in a longitudinal study of experimental brain tumors. This study is favorable to the new model of tumor angiogenesis, with successive vessel cooption, regression and growth mediated by angiopoietins and VEGF.

PMID:
12174896
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center